Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
11.03
2022
Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
11.01
2022
Addex Increases Issued Share Capital to Create Treasury Shares
09.20
2022
Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
08.18
2022
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
08.15
2022
Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
08.12
2022
Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
07.26
2022
Addex Completes $4.2 Million Equity Financing
07.22
2022
Addex Raises $4.2 million in Equity Financing
07.21
2022
Addex Provides Corporate Update and Financial Guidance
07.21
2022
Addex Completes Reduction in Nominal Value of Shares
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back